|
Nventa Biopharmaceuticals Corporation was a Canadian incorporated biopharmaceutical company headquartered in San Diego, California developing therapeutics for the treatment of viral infections and cancer, focusing on diseases caused by human papillomavirus (HPV). Nventa is currently the only company applying heat shock protein (Hsp) technology to target the over 20 million Americans already infected with HPV.〔(【引用サイトリンク】title=Genital HPV Infection: CDC Fact Sheet )〕 Previously headquartered in Victoria, British Columbia, Canada, the company’s common stock traded on the Toronto Stock Exchange under the symbol: NVN. ==Development Programs== The company’s lead candidate, HspE7, is a novel therapeutic vaccine intended for the treatment of HPV-related diseases. HspE7 is derived from Nventa’s patented CoVal fusion platform that uses recombinant DNA technology to covalently fuse heat shock proteins to target antigens, thereby stimulating cellular immune system responses to specific diseases. Nventa is developing HspE7 in combination with the Toll-like receptor 3 (TLR3) agonist adjuvant Poly-ICLC for multiple indications, including Cervical Intraepithelial Neoplasia (also known as cervical dysplasia or CIN), Genital Warts, Cervical Cancer, and head and neck cancers. According to the annual information form, for the year ending December 31, 2009, provided on Akela Pharma's website, scientific research funding has ceased for HspE7. Nventa is also developing two additional therapeutic vaccine programs based on its CoVal technology—a Hsp – HBV (hepatitis B) fusion, and prototypes of Hsp fusion proteins with influenza antigens. In June 2008, Nventa announced the development of a proprietary vaccine adjuvant, Poly IC – Poly Arginine (Poly-ICR), for use with both therapeutic and prophylactic vaccines. Poly-ICR is a TLR3 agonist that, when combined with a disease-specific antigen, can induce both cytotoxic (T cell) and antibody (B cell) immune responses against that antigen. As yet unpublished pre-clinical data indicate that Poly-ICR, in combination with a tumor-associated antigen, increases antigen-specific CD8 T-cell levels, while both inducing regression of tumors and preventing tumor growth in mouse models.〔Company Press Release, “NVENTA DEVELOPS PROPRIETARY VACCINE ADJUVANT” / (June 18, 2008 )〕 The company developed Poly-ICR for both internal use and for external licensing opportunities. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Nventa Biopharmaceuticals Corporation」の詳細全文を読む スポンサード リンク
|